Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

rozanolixizumab 7zilucoplan 6efgartigimod alfa 5eculizumab 4telitacicept 3ravulizumab 3Tacrolimus 3Rituximab 3Amifampridine 3Prednisone 2Mycophenolic Acid 2HBM9161 2satralizumab 1remibrutinib 1iptacopan 1inebilizumab 1Thymectomy 1Sugars 1Steroids 1Sodium Chloride 1Pyridostigmine Bromide 1Prednisolone 1Plasmapheresis 1Leflunomide 1Immunoglobulins, Intravenous 1Hizentra 1Cladribine 1Azathioprine 1Alkalies 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Myasthenia Gravis × Leflunomide × Clear all
NCT01727193 2022-04-14

The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy

First Affiliated Hospital, Sun Yat-Sen University

Phase 3 Completed
290 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡